The renaissance of primary aldosteronism: what has it taught us?

Stowasser, Michael and Gordon, Richard Douglas (2013) The renaissance of primary aldosteronism: what has it taught us?. Heart Lung and Circulation, 22 6: 412-420. doi:10.1016/j.hlc.2013.01.006


Author Stowasser, Michael
Gordon, Richard Douglas
Title The renaissance of primary aldosteronism: what has it taught us?
Journal name Heart Lung and Circulation   Check publisher's open access policy
ISSN 1443-9506
1444-2892
Publication date 2013-06
Sub-type Article (original research)
DOI 10.1016/j.hlc.2013.01.006
Open Access Status
Volume 22
Issue 6
Start page 412
End page 420
Total pages 9
Place of publication Australia
Publisher Elsevier Australia
Collection year 2014
Language eng
Formatted abstract
The growing realisation since the early 1990s that primary aldosteronism (PA) is a much more common cause of hypertension than previously thought, and that aldosterone excess has adverse effects that are at least partly independent of blood pressure, has been the main driving force for a renaissance in clinical and research interest in PA. This has generated a wealth of new knowledge regarding (1) PA's high prevalence, (2) the extent of non-BP dependent cardiovascular and renal organ damage and morbidity and reduced quality of life associated with PA, all of which appear to be at least partly ameliorated by specific treatment (especially surgical) directed against excessive aldosterone action, (3) the diversity of adrenal histopathology associated with PA and the need to subdivide patients based on glucocorticoid remediability (by genetic testing for the hybrid gene mutation causing familial hyperaldosteronism type I, FH-I) and lateralisation on adrenal venous sampling in order to ensure optimal treatment, (4) the value of elucidating genetic bases for PA in terms of improving detection, understanding of pathogenesis and treatment, as illustrated by the determination of the genetic basis of FH-I, and (5) the genetic basis of more common forms including aldosterone-producing adenoma. From the clinical perspective, the principal lesson learnt is that PA, being a common cause of cardiovascular morbidity and reduced quality of life reversible by specific treatment, is worth looking for.
Keyword Primary aldosteronism
Prevalence
Hypertension
Cardiovascular morbidity
Subtype differentiation
Genetics
Hyperaldosteronism type-II
Glucocorticoid-remediable aldosteronism
Intima-media thickness
Plasma-renin activity
Quality-of-life
Familial hyperaldosteronism
Hypertensive patients
KCNJ5 mutations
Blood-pressure
Unilateral adrenalectomy
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 21 Jul 2013, 00:05:42 EST by System User on behalf of Medicine - Greenslopes Private Hospital